A PHASE II TRIAL ADDRESSING FEASIBILITY AND ACTIVITY OF CLARITHROMYCIN + LENALIDOMIDE COMBINATION: A FULL ORAL TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA
Latest Information Update: 22 Jan 2022
At a glance
- Drugs Clarithromycin (Primary) ; Lenalidomide (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Acronyms CLEO
- 04 Jun 2021 Planned End Date changed from 1 Feb 2030 to 1 Nov 2029.
- 21 Jun 2020 Primary endpoint has not been met. (Tumor response assessment), according to results presented at the 25th Congress of the European Haematology Association.
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association